CAR-T Beyond Cancer: The Autoimmune Revolution Nobody Predicted

From a single lupus patient in Erlangen to pediatric trials in Rome, allogeneic programs at Allogene, and dual-targeted CD19/CD70 designs — CAR-T cell therapy is rewriting autoimmune medicine. We map the landscape: which diseases, which constructs, and who's winning the race to scale.

By BT Research